AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters - PubMed (original) (raw)
. 2005 Aug;194(2):476-83.
doi: 10.1016/j.expneurol.2005.03.007.
Jurg M Sommer, Brian M Suzuki, Peter H Smith, Sharmila Vijay, Joseph A Vargas, John R Forsayeth, Janet Cunningham, Krys S Bankiewicz, Haihwa Kao, Jan Bernal, Glenn F Pierce, Kirk W Johnson
Affiliations
- PMID: 16022872
- PMCID: PMC3816113
- DOI: 10.1016/j.expneurol.2005.03.007
AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters
Laura M Sanftner et al. Exp Neurol. 2005 Aug.
Abstract
In this study, a modified infusion procedure and a novel infusion device designed for use in humans (Clinical Device B) were evaluated for delivery of recombinant adeno-associated virus (AAV2) to brain. The device is composed of 1.2 m of fused silica inserted through a 24.6-cm surgical steel cannula designed to fit a standard Leksell clinical stereotaxic frame and micro-infusion syringe pump. AAV2 encoding the human aromatic l-amino acid decarboxylase gene (AAV-hAADC-2) was infused into the putamen of 4 normal rhesus monkeys as a supportive study for a clinical trial in Parkinson's disease (PD) patients. Two infusion protocols were tested: a ramped procedure (slow stepwise increases in rate from 0.2 muL/min to 1 muL/min), thought to be essential for convection-enhanced delivery (CED), and a non-ramped infusion at a constant rate of 1 muL/min. The primary endpoints were safety evaluation of the infusion procedures and assessment of transgene expression at 5.5 weeks post-infusion. Clinical observations after vector infusions revealed no behavioral abnormalities during the study period. No differences in gross pathology with either the ramped or non-ramped infusion procedure were observed. Histopathology of the putamen was comparable with both procedures, and revealed only minimal localized inflammatory tissue reaction along the needle track in response to cannula placement and vector infusion. AADC immunohistochemistry demonstrated that vector was distributed throughout the putamen, with no significant difference in volume of immunostaining with either infusion procedure. Serum antibody levels against AAV2 vector exhibited a minor increase after infusion. These results validate the clinical utility of this new infusion device and non-ramped infusion conditions for intraputamenal gene therapy, and have the potential to impact a number of human diseases in which delivery of therapeutics to brain is indicated.
Figures
Fig. 1
AAV vector infusion device designed for human clinical use. The cannula () is composed of 4 layers of 304 surgical steel fused together by laser welding in a step design, ending in 23-gauge tubing. The steel cannula is lined with fused silica of 100 Am inner diameter (, red) which also forms the tip of the delivery device by extending 1 cm beyond the steel. Approximately 1.2 m of additional fused silica covered with Teflon tubing (, blue) connect to a Luer hub (). A 1-in., 23-gauge steel spacer () between the fused silica and Teflon tubing is sealed and attached to the Luer hub with medical grade cyanoacrylate glue. Dimensions are in centimeters.
Fig. 2
Immunohistochemistry for AADC in whole mounted brain sections. Brains are shown in coronal section through the infusion site at 5.5 weeks post-infusion. Panels A, B, C, and D represent the four different monkey brains analyzed in this study [MR15102M (A), MR15109M (B), R23700M (C), and R211101M (D)]. All left hemispheres received ramped infusion and all right hemispheres received non-ramped infusion. The black arrow indicates the putamen region.
Fig. 3
Immunohistochemistry for AADC at high magnification within the putamen. Immunostaining is localized to the medium spiny neurons in the putamen at 5.5 weeks post-infusion. A representative section from the hemisphere that received ramped infusion is shown in Panel A and one from the hemisphere that received non-ramped infusion is shown in Panel B. Scale bar = 100 μm.
Fig. 4
H&E-stained sections within the putamen from a representative animal, R211101M, at 5× magnification. Animal R211101M received bilateral CED of AAV-hAADC-2 using the non-ramped infusion procedure in the right hemisphere (Panel A) and the ramped infusion procedure in the left hemisphere (Panel B). Images illustrate the area adjacent to the cannula track, and were taken at the mid-caudal putamen level. Scale bar = 400 μm.
Similar articles
- Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain.
Hadaczek P, Kohutnicka M, Krauze MT, Bringas J, Pivirotto P, Cunningham J, Bankiewicz K. Hadaczek P, et al. Hum Gene Ther. 2006 Mar;17(3):291-302. doi: 10.1089/hum.2006.17.291. Hum Gene Ther. 2006. PMID: 16544978 - Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.
Cunningham J, Pivirotto P, Bringas J, Suzuki B, Vijay S, Sanftner L, Kitamura M, Chan C, Bankiewicz KS. Cunningham J, et al. Mol Ther. 2008 Jul;16(7):1267-75. doi: 10.1038/mt.2008.111. Epub 2008 Jun 3. Mol Ther. 2008. PMID: 18523450 Free PMC article. - Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, Bankiewicz KS. Ciesielska A, et al. PLoS One. 2017 Feb 6;12(2):e0169965. doi: 10.1371/journal.pone.0169965. eCollection 2017. PLoS One. 2017. PMID: 28166239 Free PMC article. - Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases.
Kumagai S, Nakajima T, Muramatsu SI. Kumagai S, et al. Expert Opin Biol Ther. 2024 Aug;24(8):773-785. doi: 10.1080/14712598.2024.2386339. Epub 2024 Jul 31. Expert Opin Biol Ther. 2024. PMID: 39066718 Review. - [AAV vector-mediated gene transfer and its application to the nervous system].
Ozawa K. Ozawa K. Rinsho Shinkeigaku. 2003 Nov;43(11):835-8. Rinsho Shinkeigaku. 2003. PMID: 15152479 Review. Japanese.
Cited by
- Genome concentration, characterization, and integrity analysis of recombinant adeno-associated viral vectors using droplet digital PCR.
Prantner A, Maar D. Prantner A, et al. PLoS One. 2023 Jan 25;18(1):e0280242. doi: 10.1371/journal.pone.0280242. eCollection 2023. PLoS One. 2023. PMID: 36696399 Free PMC article. - Improving the Efficacy and Accessibility of Intracranial Viral Vector Delivery in Non-Human Primates.
Griggs DJ, Garcia AD, Au WY, Ojemann WKS, Johnson AG, Ting JT, Buffalo EA, Yazdan-Shahmorad A. Griggs DJ, et al. Pharmaceutics. 2022 Jul 8;14(7):1435. doi: 10.3390/pharmaceutics14071435. Pharmaceutics. 2022. PMID: 35890331 Free PMC article. - Synthetic amyloid-β oligomers drive early pathological progression of Alzheimer's disease in nonhuman primates.
Yue F, Feng S, Lu C, Zhang T, Tao G, Liu J, Yue C, Jing N. Yue F, et al. iScience. 2021 Sep 30;24(10):103207. doi: 10.1016/j.isci.2021.103207. eCollection 2021 Oct 22. iScience. 2021. PMID: 34704001 Free PMC article. - Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back.
Buscara L, Gross DA, Daniele N. Buscara L, et al. J Pers Med. 2020 Nov 28;10(4):258. doi: 10.3390/jpm10040258. J Pers Med. 2020. PMID: 33260623 Free PMC article. Review. - Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease.
Richardson RM, Bankiewicz KS, Christine CW, Van Laar AD, Gross RE, Lonser R, Factor SA, Kostyk SK, Kells AP, Ravina B, Larson PS. Richardson RM, et al. J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1210-1218. doi: 10.1136/jnnp-2020-322904. Epub 2020 Jul 30. J Neurol Neurosurg Psychiatry. 2020. PMID: 32732384 Free PMC article. Review.
References
- Bankiewicz KS, Eberling JL, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000;164(1):2–14. - PubMed
- Blacklow NR, Hoggan MD, et al. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst. 1968;40(2):319–327. - PubMed
- Grimm D, Kern A, et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther. 1998;9(18):2745–2760. - PubMed
- Hornykiewicz O. Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser. 1975;3:13–21. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical